What does this research mean for the field?

The combination gene therapy of HSV-TK and IL-12 inhibits non-small cell lung cancer more effectively than either monotherapy through a bystander effect associated with Cx43 up-regulation and enhanced immune activation. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To assess the anti-tumor efficacy and mechanistic pathways of combined HSV-TK and IL-12 gene therapy in non-small cell lung cancer models.

September 3, 2026Letters in Drug Design & DiscoveryOpen Access

The combination gene therapy of HSV-TK/IL-12 inhibits non-small cell lung cancer through the bystander effect associated with Cx43 up-regulation and immune activation

View Full Paper

Ask AI

Bookmark

Authors

HZHao Zheng XCXiaoping Cai ZCZhuo Cao

Discussion

Member takes

Overview

Preclinical study demonstrates that combined HSV-TK and IL-12 gene therapy suppresses non-small cell lung cancer growth, indicating a potent dual cytotoxic and immunomodulatory therapeutic approach.

Key Points

To assess the anti-tumor efficacy and mechanistic pathways of combined HSV-TK and IL-12 gene therapy in non-small cell lung cancer models.
Constructed HSV-TK and IL-12 overexpression vectors in human non-small cell lung cancer lines (A549 and H1299).
Evaluated cell viability, apoptosis, bystander killing, and co-cultured human peripheral blood lymphocyte cytotoxicity following ganciclovir exposure.
Assessed in vivo tumor suppression and metastatic lung nodule formation using xenograft and tail-vein colonization mouse models.
HSV-TK and IL-12 combination therapy significantly triggered apoptosis in A549 and H1299 cells, with ganciclovir reducing cell viability in a dose-dependent manner (P < 0.05).
Bystander-mediated tumor killing correlated positively with both the proportion of TK-expressing cells and connexin 43 levels, while increasing lymphocyte proliferation and cytotoxicity (P < 0.05).
Combination gene therapy significantly suppressed xenograft tumor growth and reduced pulmonary metastatic nodule formation in mice (P < 0.05).

Cite This Study

Zheng et al. (2026) studied this question.

synapsesocial.com/papers/6a9935f3636c6408cfa7e99b https://doi.org/10.1016/j.lddd.2026.100495

View Full Paper

Ask AI

Bookmark

September 3, 2026Letters in Drug Design & DiscoveryOpen Access

The combination gene therapy of HSV-TK/IL-12 inhibits non-small cell lung cancer through the bystander effect associated with Cx43 up-regulation and immune activation

View Full Paper

Ask AI

Bookmark

Authors

HZHao Zheng XCXiaoping Cai ZCZhuo Cao

Discussion

Member takes

Overview

Preclinical study demonstrates that combined HSV-TK and IL-12 gene therapy suppresses non-small cell lung cancer growth, indicating a potent dual cytotoxic and immunomodulatory therapeutic approach.

Key Points

To assess the anti-tumor efficacy and mechanistic pathways of combined HSV-TK and IL-12 gene therapy in non-small cell lung cancer models.
Constructed HSV-TK and IL-12 overexpression vectors in human non-small cell lung cancer lines (A549 and H1299).
Evaluated cell viability, apoptosis, bystander killing, and co-cultured human peripheral blood lymphocyte cytotoxicity following ganciclovir exposure.
Assessed in vivo tumor suppression and metastatic lung nodule formation using xenograft and tail-vein colonization mouse models.
HSV-TK and IL-12 combination therapy significantly triggered apoptosis in A549 and H1299 cells, with ganciclovir reducing cell viability in a dose-dependent manner (P < 0.05).
Bystander-mediated tumor killing correlated positively with both the proportion of TK-expressing cells and connexin 43 levels, while increasing lymphocyte proliferation and cytotoxicity (P < 0.05).
Combination gene therapy significantly suppressed xenograft tumor growth and reduced pulmonary metastatic nodule formation in mice (P < 0.05).

Cite This Study

Zheng et al. (2026) studied this question.

synapsesocial.com/papers/6a9935f3636c6408cfa7e99b https://doi.org/10.1016/j.lddd.2026.100495

View Full Paper

Ask AI

Bookmark